Brigatinib Bei ALK-positivem NSCLC

Im Focus Onkologie
doi 10.1007/s15015-017-3548-8
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Neue Chance Bei ALK-positivem NSCLC

Info Onkologie
2013English

P2.13-03 Real-Life Experience With Brigatinib in Pretreated EML4-ALK Translocated NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Bei Positivem Hormonrezeptorstatus Endokrin Therapieren

Info Onkologie
2011English

PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

1330: Brigatinib Efficacy and Safety in Patients (Pts) With Anaplastic Lymphoma Kinase (ALK)-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) in a Phase 1/2 Trial

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Adjuvante Immuntherapie Bei NSCLC

Im Focus Onkologie
2016English

ALK (D5F3) CDx: An Immunohistochemistry Assay to Identify ALK-positive NSCLC Patients

Pharmacogenomics and Personalized Medicine
Molecular MedicinePharmacology
2018English

Sandler-Schema Bei NSCLC Bestätigt

Info Onkologie
2012English

Paclitaxel Bei NSCLC Angepasst Dosieren

Im Focus Onkologie
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy